To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated
patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose …

The emergence of coronavirus disease 2019 (COVID-19), caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected many countries throughout …

Objective To examine the association of COVID-19 convalescent plasma transfusion with
mortality and the differences between subgroups in hospitalized patients with COVID-19 …

Convalescent plasma has been used worldwide to treat patients hospitalized with
coronavirus disease 2019 (COVID-19) and prevent disease progression. Despite global …

New emerging severe acute respiratory syndrome 2 (SARS-CoV-2) has caused a worldwide
pandemic. Several animal models of coronavirus disease 2019 (COVID-19) have been …

Introduction When the COVID-19 pandemic struck no specific therapies were available and
many turned to COVID-19 convalescent plasma (CCP), a form of antibody therapy. The …

Background There is still a lack of consensus on the efficacy of convalescent plasma (CP)
treatment in COVID‐19 patients. We performed a systematic review and meta‐analysis to …

The purpose of this systematic review and meta‐analysis was to examine clinical outcomes
associated with convalescent plasma therapy in COVID‐19 patients. We performed a …

Exposure to severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2) prompts
humoral immune responses in the human body. As the auxiliary diagnosis of a current …

Background As SARS-CoV-2 continues to spread worldwide, it has already resulted in over
110 million cases and 2.5 million deaths. Currently, there are no effective COVID-19 …